Clinical endpoints for assessing bisphosphonate efficacy in the prevention of skeletal complications of bone metastases

European Urology, Supplements

Volumn 3, Issue 5 SPEC. ISS., 2004, Pages 34-39

  Major, Pierre P ^a   Cook, Richard J ^b  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Bisphosphonates; Endpoints; Multiple event analysis; Prostate cancer; Survival adjusted cumulative incidence; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE DISEASE; BONE METASTASIS; CONFERENCE PAPER; DRUG EFFICACY; EVALUATION; HUMAN; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; RISK;

EID: 7244226358     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2004.08.010     Document Type: Conference Paper

References (29)

1. R.E. Coleman Skeletal complications of malignancy Cancer 80 Suppl 1997 1588 1594
2. R.J. Cook, and P. Major Methodology for treatment evaluation in patients with cancer metastatic to bone J Natl Cancer Inst. 93 2001 534 538
3. F. Saad, and C.C. Schulman Role of bisphosphonates in prostate cancer Eur Urol. 45 2004 26 34
4. ® (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate Cancer Invest. 20 Suppl 2 2002 45 54
5. F. Saad Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid Semin Oncol. 29 Suppl 21 2002 19 27
6. I. Elomaa, T. Kylmälä, T. Tammela, J. Viitanen, J. Ottelin, and M. Ruutu Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer Int Urol Nephrol 24 1992 159 166
7. T. Kylmala, T. Taube, T.L. Tammela, L. Risteli, J. Risteli, and I. Elomaa Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer Br J Cancer. 76 1997 939 942
8. P. Strang, S. Nilsson, S. Brandstedt, J. Sehlin, G. Borghede, and E. Varenhorst The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer Anticancer Res. 17 1997 4717 4721
9. D.S. Ernst, I.F. Tannock, E.W. Winquist, P.M. Venner, L. Reyno, and M.J. Moore Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain J Clin Oncol. 21 2003 3335 3342
10. P.P. Major, and R. Cook Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints Am J Clin Oncol. 25 Suppl 1 2002 S10 S18
11. P.P. Major, R.J. Cook, R. Tozer, and H. Hirte Bisphosphonates for bone metastases in breast cancer patients: trial design issues and evaluation of published studies Curr Oncol. 5 1998 181 187
12. J.R. Johnson, G. Williams, and R. Pazdur End points and United States Food and Drug Administration approval of oncology drugs J Clin Oncol. 21 2003 1404 1411
13. F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe for the Zoledronic Acid Prostate Cancer Study Group Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst. 96 2004 879 882
14. L.S. Rosen, D. Gordon, M. Kaminski, A. Howell, A. Belch, and J. Mackey Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 2003 1735 1744
15. L.S. Rosen, D. Gordon, S. Tchekmedyian, R. Yanagihara, V. Hirsh, and M. Krzakowski Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol. 21 2003 3150 3157
16. F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, and L. Lacombe A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst. 94 2002 1458 1468
17. P.K. Andersen, and R.D. Gill Cox's regression model for counting processes: a large sample study Ann Stat. 10 1982 1100 1120
18. R.J. Cook, and J.F. Lawless Interim monitoring of longitudinal comparative studies with recurrent event responses Biometrics 52 1996 1311 1323
19. D. Ghosh, and D.Y. Lin Nonparametric analysis of recurrent events and death Biometrics 56 2000 554 562
20. R.C. Pelger, V. Soerdjbalie-Maikoe, and N.A. Hamdy Strategies for management of prostate cancer-related bone pain Drugs Aging. 18 2001 899 911
21. K. Teske, R.L. Daut, and C.S. Cleeland Relationships between nurses' observations and patients' self-reports of pain Pain 16 1983 289 296
22. B.E. Hillner, J.N. Ingle, J.R. Berenson, N.A. Janjan, K.S. Albain, and A. Lipton American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel J Clin Oncol. 18 2000 1378 1391
23. B.E. Hillner, J.N. Ingle, R.T. Chlebowski, J. Gralow, G.C. Yee, and N.A. Janjan American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol. 21 2003 4042 4057. Erratum in: J Clin Oncol 2004;22:1351
24. J.J. Body, I.J. Diel, M.R. Lichinitser, E.D. Kreuser, W. Dornoff, V.A. Gorbunova, M. Budde, B.M. Bergstrom MF# 4265 Study Group Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol. 14 2003 1399 1405
25. R.J. Cook, and J.F. Lawless Marginal analysis of recurrent events and a terminating event Stat Med. 16 1997 911 924
26. R.J. Cook, B. Chen, and P. Major Marginal analysis of point processes with competing risks N. Balakrishnan C.R. Rao Handbook of statistics 23: advances in survival analysis 2004 Elsevier Oxford 349 361
27. B.E. Chen, and R.J. Cook Tests for multivariate recurrent events in the presence of a terminal event Biostatistics 5 2004 129 143
28. L.S. Rosen, D. Gordon, N.S. Tchekmedyian, R. Yanagihara, V. Hirsh, M. Krzakowski on behalf of the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial Cancer 100 2004 2613 2621
29. P.P. Major, R.J. Cook, B.L. Chen, and M. Zheng Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone [abstract] Proc Am Soc Clin Oncol. 22 2003 762